Use of the LC16m8 Smallpox Vaccine in Immunocompromised Individuals Is Still Too Risky.
about
British HIV Association Guidelines on the Use of Vaccines in HIV-Positive Adults 2015.Reply to "Use of the LC16m8 Smallpox Vaccine in Immunocompromised Individuals Is Still Too Risky".Protection of Mice from Lethal Vaccinia Virus Infection by Vaccinia Virus Protein Subunits with a CpG Adjuvant.Challenges and Achievements in Prevention and Treatment of Smallpox.
P2860
Use of the LC16m8 Smallpox Vaccine in Immunocompromised Individuals Is Still Too Risky.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Use of the LC16m8 Smallpox Vaccine in Immunocompromised Individuals Is Still Too Risky.
@en
Use of the LC16m8 Smallpox Vaccine in Immunocompromised Individuals Is Still Too Risky.
@nl
type
label
Use of the LC16m8 Smallpox Vaccine in Immunocompromised Individuals Is Still Too Risky.
@en
Use of the LC16m8 Smallpox Vaccine in Immunocompromised Individuals Is Still Too Risky.
@nl
prefLabel
Use of the LC16m8 Smallpox Vaccine in Immunocompromised Individuals Is Still Too Risky.
@en
Use of the LC16m8 Smallpox Vaccine in Immunocompromised Individuals Is Still Too Risky.
@nl
P356
P1476
Use of the LC16m8 Smallpox Vaccine in Immunocompromised Individuals Is Still Too Risky.
@en
P2093
Yehuda L Danon
P2860
P356
10.1128/CVI.00782-14
P50
P577
2015-05-01T00:00:00Z